CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Trauma Clinical Trial

— CAVALIER  

Official title:

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05958342
• Other study ID #: STUDY23040043
• Secondary ID: W81XWH-6-D-0024
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: July 2024
• Est. completion date: March 2028

Study information

• Verified date: June 2024
• Source: University of Pittsburgh
• Contact: Jason Sperry, MD
• Phone: 4128028270
• Email: sperryjl[@]upmc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) Trial is a proposed 4 year, double-blind, mutli-center, prehospital and early in hospital phase randomized trial designed to determine the efficacy and safety of prehospital calcium and early in hospital vasopressin in patients at risk of hemorrhagic shock.

Description:

Resuscitation strategies for the acutely injured patient in hemorrhagic shock have evolved. Patients benefit from receiving less crystalloid in favor of blood transfusions with balanced ratios of plasma and platelets or whole blood resuscitation. These resuscitation practices are termed Damage Control Resuscitation and have been incorporated into resuscitation protocols in Level I trauma centers across the country. Damage Control Resuscitation represents standard practice for military and civilian trauma. Despite these changes, deaths from traumatic hemorrhage continue to occur in the first hours following trauma center arrival, underscoring the importance of early, novel interventions.

Hypocalcemia following traumatic injury is exceedingly common following severe traumatic injury in patients at risk of hemorrhagic shock. During hemorrhagic shock resuscitation, pathways reliant upon calcium such as platelet function, intrinsic and extrinsic hemostasis, and cardiac contractility are disrupted. Citrate containing transfusion products are known to further reduce calcium levels through chelation during trauma resuscitation. Hypocalcemia has consistently been shown to be independently associated with the risk of large volume blood transfusion and mortality. Current management practices include calcium replacement during the in hospital phase of care in patients receiving blood products. Early calcium replacement in patients at risk of hemorrhage and hypocalcemia may mitigate coagulopathy, maintain hemostasis, improve hemodynamics and outcomes, and may reduce complications attributable to hemorrhagic shock.

Arginine vasopressin is a physiologic hormone released by the posterior pituitary in response to hypotension and is commonly used as a vasopressor for critically ill patients for the treatment of hypotension due to multiple causes including sepsis. Prolonged hemorrhagic shock has the potential to alter systemic vasomotor tone which can progress to refractory/recalcitrant hypotension. Patients receiving resuscitation for hemorrhage are at risk of vasopressin deficiency. Vasopressin may improve hemostasis by enhancing platelet function and augmenting clot formation. Vasopressin infusion soon after injury in patients in hemorrhagic shock has been demonstrated to be safe and result in a reduction in blood transfusion requirements and a lower incidence of deep venous thrombosis.

Whole blood, red cells, and blood components are a precious and limited resource. Trauma resuscitation adjuncts such as early calcium and vasopressin may provide benefit when transfusion products are limited and may provide additional benefit even when transfusion capabilities remain robust. Due to their action on coagulation and hemodynamic cascades in the injured patient, these resuscitation adjuncts have the potential to interact and provide additive benefit to the injured patient. However, safety and efficacy of prehospital calcium and early in hospital vasopressin remain inadequately characterized. Enrolled patients may participate in the prehospital phase (calcium), in-hospital phase (vasopressin), or both. The aims of the CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) trial are to determine the efficacy and safety of prehospital calcium supplementation and early in hospital vasopressin infusion as compared to standard care resuscitation in patients at risk of hemorrhagic shock and to appropriately characterize any additive effect of both resuscitation adjunct interventions.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1050
• Est. completion date: March 2028
• Est. primary completion date: March 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

Prehospital Phase:

Injured patients at risk of hemorrhagic shock being transported from scene or referral hospital to a participating CAVALIER trial site who meet the following criteria:

1A. Systolic blood pressure = 90mmHg and tachycardia (HR = 108) at scene, at outside hospital, or during anticipated transport to a participating CAVALIER trial site

OR

1B. Systolic blood pressure = 70mmHg at scene, at outside hospital, or during anticipated transport to a participating CAVALIER trial site

Early In-Hospital Phase:

Injured patients at a participating CAVALIER trial site at risk of hemorrhagic shock who meet the following criteria:

1A. Systolic blood pressure = 90mmHg and tachycardia (HR = 108) at scene, at outside hospital, during transport, or in emergency department of a participating CAVALIER trial site

OR

1B. Systolic blood pressure = 70mmHg at scene, at outside hospital, during transport, or in emergency department of a participating CAVALIER trial site

AND

2.Blood/blood component transfusion initiated in prehospital setting or deemed clinically indicated within 60 minutes of arrival at the enrolling trauma center

AND 3. Clinical team deems Operating Room for major hemorrhage control procedure (e.g., laparotomy, thoracotomy, vascular exploration or extremity amputation) indicated within 60 minutes of arrival at the enrolling trauma center

AND

4. Anticipated admission to intensive care unit (ICU)

Exclusion Criteria:

Prehospital Phase

1. Wearing NO CAVALIER opt-out bracelet

2. Age > 90 or < 18 years of age

3. Isolated fall from standing injury mechanism

4. Known prisoner

5. Known pregnancy

6. Traumatic arrest with > 5 minutes of CPR without return of vital signs

7. Brain matter exposed or penetrating brain injury

8. Isolated drowning or hanging victims

9. Objection to study voiced by subject or family member at the scene or at the trauma center

10. Inability to obtain IV/IO access

Early In-Hospital Phase:

1. Wearing NO CAVALIER opt-out bracelet

2. Age > 90 or < 18 years of age

3. Isolated fall from standing injury mechanism

4. Known prisoner

5. Known pregnancy

6. Traumatic arrest with > 5 minutes of CPR without return of vital signs

7. Brain matter exposed or penetrating brain injury

8. Isolated drowning or hanging victims

9. Objection to study voiced by subject or family member at the scene or at the trauma center

10. Inability to obtain IV access

Related Conditions & MeSH terms

• Hemorrhage
• Trauma

Intervention

Drug:
• Calcium Gluconate
1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes
• Vasopressin
4 unit vasopressin bolus followed by vasopressin infusion at 0.04 U/min for eight hours
• saline placebo
saline placebo volume matched to prehospital or in hospital phase

Locations

Country	Name	City	State
United States	University of Pittsburgh	Pittsburgh	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Jason Sperry	United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with 30-day mortality	all cause mortality within 30 days	from randomization to death or 30 days, whichever comes first
Secondary	Number of participants with 6-hour mortality	all cause mortality within 6 hours	from randomization to death or 6 hours, whichever comes first
Secondary	Number of participants with 24-hour mortality	all cause mortality within 24 hours	from randomization to death or 24 hours, whichever comes first
Secondary	Number of participants with In-hospital mortality	death prior to hospital discharge	In hospital mortality from time of randomization to death or 30 days, whichever comes first
Secondary	Number of participants with Death from hemorrhage	Death from hemorrhage adjudicated by the site investigator	from randomization to death or 30 days, whichever comes first
Secondary	Number of participants with Death from brain injury	Death from brain injury adjudicated by the site investigator	from randomization to death or 30 days, whichever comes first
Secondary	Blood and blood component transfusion requirements in the initial 6 hours	number of units transfused and type	from randomization to 6 hours
Secondary	Blood and blood component transfusion requirements in the initial 24 hours	number of units transfused and type	from randomization to 24 hours
Secondary	Incidence of Multiple Organ Failure (MOF)	Evaluated via the Denver Post injury Multiple Organ Failure Score, characterized as an incidence rate (percentage) and as MOF free days. Patients never admitted to ICU or with length of stay less than 48 hours will have a score of 0. A summary Denver score of >3 will be classified as MOF.	Scores determined daily until up to Day 7 or ICU discharge, whichever comes first
Secondary	Incidence of nosocomial infection	Utilizing the CDC criteria for diagnosis of hospital acquired pneumonia and blood stream infection	from randomization to death or 30 days
Secondary	Time to hemostasis	Determined by ability to reach nadir transfusion requirement of 1 unit of red blood cells in a 60 minute period in the first 4 hours following arrival. In the absence of ability to obtain hemostasis within the first 4 hours, the patient will be designated "non-hemostasis"	hospital arrival to 4 hours
Secondary	Incidence of coagulopathy by thromboelastography (TEG)	TEG date collected only when obtained as part of clinical	within 4 hours of arrival plus or minus 12
Secondary	Incidence of coagulopathy by thromboelastography (TEG)	TEG date collected only when obtained as part of clinical	within 24 hours of arrival plus or minus 12
Secondary	ICU free days	number of days the patient is alive and not admitted to ICU subtracted from 30	From hospital arrival to death or 30 days
Secondary	Hospital free days	number of days the patient is alive and not admitted to hospital subtracted from 30	From hospital arrival to death or 30 days